Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeloProsed is a marketed pharmaceutical combination product developed by G. Pohl-Boskamp for the symptomatic relief of colds and flu-like infections. It contains two active ingredients: paracetamol (1000 mg), which acts as an analgesic and antipyretic, and phenylephrine hydrochloride (12.2 mg), which serves as a sympathomimetic decongestant. The product is uniquely formulated as a powder for oral administration that dissolves directly in the mouth without the need for water, facilitating convenient use. It is indicated for adults and adolescents aged 12 years and older to treat symptoms such as pain, headache, sore throat, and fever, particularly when accompanied by nasal congestion. Although G. Pohl-Boskamp is well-known for herbal medicines, GeloProsed is a conventional small-molecule pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GeloProsed.